Copanlisib with standard immunochemotherapy in relapsed iNHL
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Copanlisib with standard immunochemotherapy in relapsed iNHL

Sponsor: Bayer HealthCare Pharmaceuticals, Inc.

CHRONOS-4: A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma. Eligible diagnoses include: - Follicular lymphoma - Small lymphocytic lymphoma - Lymphoplasmacytic lymphoma / Waldenström Macroglobulinemia - Marginal zone lymphoma